Ironwood Pharmaceuticals Inc (IRWD)

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global...

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – –...

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

– LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth...

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

– Surveyed HCPs identified reduction of days on TPN as a top priority – – Improved quality of life, lower risk of infection and thrombosis viewed...

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

– Separate poster will feature long-term safety and tolerability data from STARS clinical trial program of apraglutide in adults with SBS who are...